November 11, 2021
1 min watch
Save
LumiThera announces acquisition of Diopsys
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW ORLEANS — LumiThera announced it has entered into a definitive merger agreement with Diopsys, according to a press release.
In the agreement, Diopsys stockholders will receive stock in LumiThera, and Diopsys will become a wholly owned subsidiary of LumiThera.
“As of this morning, we announced Diopsys and LumiThera are going to merge to form a theranostic company for dry age-related macular degeneration and other degenerative ocular disease and damage,” Clark Tedford, CEO of LumiThera, told Healio/OSN in a video recorded at the Eyecelerator meeting here.
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.